Rang	Name	Position
1	Mr. Joseph Todisco MBA	CEO & Chairman of the Board of Directors
2	Ms. Elizabeth Masson-Hurlburt B.A.	Executive VP and Chief Operating & Commercial Officer
3	Ms. Kaufman Beth Zelnick Esq.	EVP, Chief Legal and Compliance Officer & Corporate Secretary
4	Ms. Susan Blum	EVP & Chief Financial Officer
5	Ms. Beth Steinbrenner	SVP & Chief Human Resource Officer
6	Dr. Matthew T. David M.D.	EVP & Chief Business Officer
7	Donna Ucci	Senior VP & Head of Global Quality
8	Dr. Tushar Mukherjee	Senior VP & Head of Technical Operations
9	Dr. Peter Sullivan BCOP, Pharm.D.	Senior Vice President of Market Access
10	Mr. Jared L. Crandon Pharm.D.	Executive Director of Clinical Portfolio Management

Aufteilung der Investoren

Rang	Inhaber	Anteile	Wert
1	BlackRock Inc	8,11%	46,67 Mio. USD
2	Deep Track Capital, LP	8,05%	46,30 Mio. USD
3	Vanguard Capital Management, LLC	4,02%	23,14 Mio. USD
4	State Street Corp	2,97%	17,10 Mio. USD
5	Royce & Associates, LP	2,79%	16,06 Mio. USD
6	Geode Capital Management, LLC	2,50%	14,37 Mio. USD
7	UBS Group AG	2,41%	13,86 Mio. USD
8	Oberweis Asset Management Inc	1,70%	9,77 Mio. USD
9	Alyeska Investment Group, L.P.	1,09%	6,27 Mio. USD
10	Marshall Wace Asset Management Ltd	1,00%	5,75 Mio. USD
11	Northern Trust Corp	0,97%	5,58 Mio. USD
12	Vanguard Portfolio Management, LLC	0,91%	5,23 Mio. USD
13	Pacer Advisors, INC.	0,81%	4,68 Mio. USD
14	HRT FINANCIAL LLC	0,80%	4,62 Mio. USD
15	Trexquant Investment LP	0,80%	4,60 Mio. USD
16	Charles Schwab Investment Management Inc	0,79%	4,56 Mio. USD
17	Armistice Capital, LLC	0,64%	3,69 Mio. USD
18	Vanguard Fiduciary Trust Co	0,62%	3,57 Mio. USD
19	The Goldman Sachs Group Inc	0,60%	3,44 Mio. USD
20	Hennion & Walsh Asset Management Inc	0,56%	3,24 Mio. USD